Drug resistance profile and clonality of Plasmodium falciparum parasites in Cape Verde: the 2017 malaria outbreak.
Adolescent
Adult
Aged
Aged, 80 and over
Antimalarials
/ therapeutic use
Cabo Verde
/ epidemiology
Child
Child, Preschool
Disease Outbreaks
Drug Resistance
/ genetics
Female
Humans
Malaria, Falciparum
/ epidemiology
Male
Middle Aged
Plasmodium falciparum
/ drug effects
Polymorphism, Genetic
Protozoan Proteins
/ genetics
Young Adult
Drug resistance
Genetics
Malaria
Plasmodium falciparum
Sequencing
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
31 Mar 2021
31 Mar 2021
Historique:
received:
24
11
2020
accepted:
17
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
9
9
2021
Statut:
epublish
Résumé
Cape Verde is an archipelago located off the West African coast and is in a pre-elimination phase of malaria control. Since 2010, fewer than 20 Plasmodium falciparum malaria cases have been reported annually, except in 2017, when an outbreak in Praia before the rainy season led to 423 autochthonous cases. It is important to understand the genetic diversity of circulating P. falciparum to inform on drug resistance, potential transmission networks and sources of infection, including parasite importation. Enrolled subjects involved malaria patients admitted to Dr Agostinho Neto Hospital at Praia city, Santiago island, Cape Verde, between July and October 2017. Neighbours and family members of enrolled cases were assessed for the presence of anti-P. falciparum antibodies. Sanger sequencing and real-time PCR was used to identify SNPs in genes associated with drug resistance (e.g., pfdhfr, pfdhps, pfmdr1, pfk13, pfcrt), and whole genome sequencing data were generated to investigate the population structure of P. falciparum parasites. The study analysed 190 parasite samples, 187 indigenous and 3 from imported infections. Malaria cases were distributed throughout Praia city. There were no cases of severe malaria and all patients had an adequate clinical and parasitological response after treatment. Anti-P. falciparum antibodies were not detected in the 137 neighbours and family members tested. No mutations were detected in pfdhps. The triple mutation S108N/N51I/C59R in pfdhfr and the chloroquine-resistant CVIET haplotype in the pfcrt gene were detected in almost all samples. Variations in pfk13 were identified in only one sample (R645T, E668K). The haplotype NFD for pfmdr1 was detected in the majority of samples (89.7%). Polymorphisms in pfk13 associated with artemisinin-based combination therapy (ACT) tolerance in Southeast Asia were not detected, but the majority of the tested samples carried the pfmdr1 haplotype NFD and anti-malarial-associated mutations in the the pfcrt and pfdhfr genes. The first whole genome sequencing (WGS) was performed for Cape Verdean parasites that showed that the samples cluster together, have a very high level of similarity and are close to other parasites populations from West Africa.
Sections du résumé
BACKGROUND
BACKGROUND
Cape Verde is an archipelago located off the West African coast and is in a pre-elimination phase of malaria control. Since 2010, fewer than 20 Plasmodium falciparum malaria cases have been reported annually, except in 2017, when an outbreak in Praia before the rainy season led to 423 autochthonous cases. It is important to understand the genetic diversity of circulating P. falciparum to inform on drug resistance, potential transmission networks and sources of infection, including parasite importation.
METHODS
METHODS
Enrolled subjects involved malaria patients admitted to Dr Agostinho Neto Hospital at Praia city, Santiago island, Cape Verde, between July and October 2017. Neighbours and family members of enrolled cases were assessed for the presence of anti-P. falciparum antibodies. Sanger sequencing and real-time PCR was used to identify SNPs in genes associated with drug resistance (e.g., pfdhfr, pfdhps, pfmdr1, pfk13, pfcrt), and whole genome sequencing data were generated to investigate the population structure of P. falciparum parasites.
RESULTS
RESULTS
The study analysed 190 parasite samples, 187 indigenous and 3 from imported infections. Malaria cases were distributed throughout Praia city. There were no cases of severe malaria and all patients had an adequate clinical and parasitological response after treatment. Anti-P. falciparum antibodies were not detected in the 137 neighbours and family members tested. No mutations were detected in pfdhps. The triple mutation S108N/N51I/C59R in pfdhfr and the chloroquine-resistant CVIET haplotype in the pfcrt gene were detected in almost all samples. Variations in pfk13 were identified in only one sample (R645T, E668K). The haplotype NFD for pfmdr1 was detected in the majority of samples (89.7%).
CONCLUSIONS
CONCLUSIONS
Polymorphisms in pfk13 associated with artemisinin-based combination therapy (ACT) tolerance in Southeast Asia were not detected, but the majority of the tested samples carried the pfmdr1 haplotype NFD and anti-malarial-associated mutations in the the pfcrt and pfdhfr genes. The first whole genome sequencing (WGS) was performed for Cape Verdean parasites that showed that the samples cluster together, have a very high level of similarity and are close to other parasites populations from West Africa.
Identifiants
pubmed: 33789667
doi: 10.1186/s12936-021-03708-z
pii: 10.1186/s12936-021-03708-z
pmc: PMC8011132
doi:
Substances chimiques
Antimalarials
0
Protozoan Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Références
Nucleic Acids Res. 2016 Jul 8;44(W1):W242-5
pubmed: 27095192
Clin Infect Dis. 2016 Feb 1;62(3):323-333
pubmed: 26486699
Am J Trop Med Hyg. 2009 Sep;81(3):525-8
pubmed: 19706926
Sci Rep. 2017 Aug 7;7(1):7389
pubmed: 28785011
Malar J. 2014 Aug 06;13:300
pubmed: 25098280
Emerg Infect Dis. 2015 Mar;21(3):490-2
pubmed: 25695257
J Infect Dis. 2007 Jan 1;195(1):134-41
pubmed: 17152017
Malar J. 2018 Oct 30;17(1):398
pubmed: 30376843
Infect Drug Resist. 2018 Aug 28;11:1329-1338
pubmed: 30214253
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Infect Dis. 2009 Mar 1;199(5):750-7
pubmed: 19210165
Nat Commun. 2016 May 18;7:11553
pubmed: 27189525
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30559133
N Engl J Med. 2017 Mar 9;376(10):991-3
pubmed: 28225668
PLoS One. 2019 Mar 18;14(3):e0213686
pubmed: 30883571
Am J Trop Med Hyg. 2014 Jul;91(1):54-61
pubmed: 24799371
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
J Infect Dis. 2015 Apr 15;211(8):1352-5
pubmed: 25367300
Sci Rep. 2019 Jun 4;9(1):8287
pubmed: 31164664
PLoS One. 2014 Aug 21;9(8):e105690
pubmed: 25144768
Infect Immun. 2004 Mar;72(3):1557-67
pubmed: 14977962
J Antimicrob Chemother. 2007 Jun;59(6):1197-9
pubmed: 17475629
Trans R Soc Trop Med Hyg. 2001 May-Jun;95(3):315-9
pubmed: 11491006
mBio. 2019 Apr 30;10(2):
pubmed: 31040246
Am J Trop Med Hyg. 2016 Nov 2;95(5):1090-1093
pubmed: 27573632
BMC Genomics. 2017 Nov 13;18(1):864
pubmed: 29132317
J Infect Dis. 2002 Feb 1;185(3):380-8
pubmed: 11807721
BMC Infect Dis. 2017 Aug 10;17(1):560
pubmed: 28797235
Parasitology. 1999 Apr;118 ( Pt 4):347-55
pubmed: 10340324
Antimicrob Agents Chemother. 2010 Mar;54(3):1200-6
pubmed: 20065051
Malar J. 2019 Mar 12;18(1):76
pubmed: 30871535
Malar J. 2008 Sep 30;7:195
pubmed: 18826573
Nature. 2012 Jul 19;487(7407):375-9
pubmed: 22722859
Trop Med Int Health. 2004 May;9(5):624-9
pubmed: 15117308
Malar J. 2013 Oct 30;12:377
pubmed: 24172030
Front Public Health. 2018 Mar 02;6:57
pubmed: 29552553
Infect Immun. 2001 May;69(5):3286-94
pubmed: 11292751
Antimicrob Agents Chemother. 2010 May;54(5):1949-54
pubmed: 20231394
PLoS One. 2015 Mar 19;10(3):e0119215
pubmed: 25789669
Malar J. 2016 Nov 29;15(1):575
pubmed: 27899115
Malar J. 2019 Mar 7;18(1):60
pubmed: 30846002
Am J Trop Med Hyg. 2014 Oct;91(4):833-843
pubmed: 25048375
Antimicrob Agents Chemother. 2015 Oct 26;60(1):624-7
pubmed: 26503652
Am J Trop Med Hyg. 2005 Mar;72(3):249-51
pubmed: 15772315
PLoS One. 2011;6(9):e23875
pubmed: 21912647
Acta Trop. 2009 Jul;111(1):78-81
pubmed: 19426667
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
Expert Rev Anti Infect Ther. 2017 Jun;15(6):527-543
pubmed: 28355493
BMC Public Health. 2019 Jul 1;19(1):850
pubmed: 31262268
J Infect Dis. 2015 Mar 1;211(5):680-8
pubmed: 25180240
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Malar J. 2014 Nov 23;13:452
pubmed: 25418416
Antimicrob Agents Chemother. 2015;59(6):3018-30
pubmed: 25753626
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Malar J. 2019 Sep 18;18(1):319
pubmed: 31533729
Malar J. 2018 Jun 19;17(1):236
pubmed: 29914468
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Emerg Infect Dis. 2014 Jul;20(7):1199-202
pubmed: 24963881
Pan Afr Med J. 2015 Jun 09;21:101
pubmed: 26516402